Co-Diagnostics, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $166,131, a slight increase from $162,910 in the same period of 2025. For the first half of 2026, the company generated $312,084 in revenue, compared to $213,187 in the first half of 2025. Despite the increase in revenue, the company experienced a net loss of $6,283,786 for the second quarter, an improvement from the $7,730,117 loss reported in the same quarter of the previous year. The net loss for the first half of 2026 was $15,423,824, compared to $15,263,388 for the first half of 2025.
The company’s operating expenses decreased to $6.3 million in the second quarter of 2026 from $8.2 million in the same quarter of 2025. This reduction was attributed to lower legal and professional services expenses, as well as decreased personnel and stock-based compensation costs. Research and development expenses for the second quarter were $4.2 million, down from $4.7 million in the prior year, reflecting a decrease in personnel-related expenses, although clinical trial costs for the Co-Dx PCR platform increased. The company’s cash and cash equivalents at the end of June 2026 stood at $3.6 million, a significant decrease from $11.9 million at the end of December 2025.
In terms of strategic developments, Co-Diagnostics has focused on enhancing its product offerings and expanding its market presence. The company is advancing its Co-Dx PCR platform, which is currently undergoing clinical studies for a tuberculosis test. Additionally, Co-Diagnostics has established a joint venture with Arabian Eagle Manufacturing to commercialize its technologies in the Middle East and North Africa. The company also completed a private placement transaction in May 2026, raising approximately $3 million, which is expected to support its ongoing operations and product development.
Operationally, Co-Diagnostics has seen a shift in its revenue sources, with 63% of its product revenue coming from the United States in the second quarter of 2026, down from 100% in the same period of 2025. The company is also actively working on regulatory submissions for its Co-Dx PCR Flu A/B and RSV multiplex test, which could further enhance its product portfolio. However, the company faces challenges, including the need for additional financing to support its operations and the ongoing uncertainty regarding its ability to continue as a going concern.
Looking ahead, Co-Diagnostics anticipates continued operating losses and cash usage in the near term. The company is exploring various financing options, including equity and debt financing, to meet its capital requirements. However, management has expressed concerns about the availability of such financing on favorable terms, which could significantly impact the company's operations and financial stability.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. develops and manufactures molecular diagnostic tests using proprietary PCR technology to detect infectious diseases and genetic traits. Its core products include PCR-based diagnostic kits for COVID-19, influenza, tuberculosis, HPV, and other pathogens, sold globally to clinical labs and health agencies. The company emphasizes affordable, rapid, and accurate testing solutions, with a focus on innovative platform development for point-of-care and at-home use.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov